Replies to post #271211 on Avid Bioservices Inc (CDMO)

[biopharm]

Janssen/Johnson Johnson closing in with Dmitry Gabrilovich and realize how important PS Targeting truly is.... heck, I believe JnJ/Janssen have known for quite some time how big PS Targeting would become.

Two Janssen/JnJ top IO guys.... now on board with Dmitry would include:

Manuel Sepulveda
https://www.linkedin.com/in/m-alejandro-sepulveda-24100739

Denis Smirnov currently Janssen... but ex On Q ity

Director, Characterization
On-Q-ity
June 2010 – May 2012 (2 years)Greater Boston Area

Development of approaches for capture and molecular characterization of circulating tumor cells.
https://www.linkedin.com/in/smirnod

Would this be the same Denis Smirnov with relative in Fargo Force? just very strange how all roads seem to pass through Fargo

anyhow... I wonder where Sue Siegel falls with GE now and
https://www.linkedin.com/in/sue-siegel-0561084

---------------------------------------------------------

Nov 3, 2009 -

On Q Ity takes off...

Sue Siegel, MDV Partner and On-Q-ity board member, added, "Mara has been at the forefront of personalized medicine and has a proven ability to bring new diagnostics to market. We are excited that the combination of a strong seasoned team and On-Q-ity's arsenal of proprietary technologies can play a key role in our nation's war on cancer and improve patient care while reducing healthcare costs."


http://www.prnewswire.com/news-releases/cancer-diagnostics-company-on-q-ity-raises-21m-in-series-a-funding-for-the-development-of-technologies-to-personalize-cancer-therapy-68846062.html

-------------------------------------------------------

Aug 1, 2011
Roche Appoints Mara G. Aspinall President of Ventana Medical Systems, Inc.

http://www.fiercebiotech.com/biotech/roche-appoints-mara-g-aspinall-president-of-ventana-medical-systems-inc-0

--------------------------------------------------------

April 10, 2013

http://www.forbes.com/sites/brucebooth/2013/04/10/on-q-ity-a-cancer-diagnostic-company-r-i-p/#4f27d2be6749

-------------------------------------------------------

Ok... so venture money all over the place studying CTC's and all of a sudden it shuts down in 2013 ? ... but in the middle of this Roche lands a key player that may know that CTC's will turn out to be a big business...

I guess so, because CTC's have flipped PS all over the place and an early on puzzle piece comes back in light now--- Ventana studying Bavi imaging may have seen the light long ago

--------------------------------------------------------
So whats everyones guess ?? That Bavi imaging that Roche was playing with was via Ventana is my best educated guess and the story gets better... well I say it does

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=92850426

---------------------------------------------------------

Well what do you know, PS Targeting and Peregrine still standing and ok, I guess it just bugs the hell out of me knowing (99.9%) that some group owns a bunch of shares that are not reporting over 5% ownership I wonder if the SEC could just find that proof and VOID all voting rights on this stock or ... something... and avoid any RS that may be required and puzzle pieces continue to drop in

[biopharm]

Dmitry Gabrilovich : Peregrine Pharmaceuticals KOL :

Follow the puzzle pieces....

New Agents, Targets Continue to Emerge in Sarcoma, Cementing Role for Immunotherapy

Shannon Connelly
Published Online:4:27 PM, Mon

November 28, 2016

Wilky: This study is designed to sort of carry immunotherapy one step further. Immunotherapy has had some dramatic responses in sarcoma, but it doesn’t work for everyone.

One of the reasons people think immunotherapy may not be effective is that potentially there are problems getting the immune cells into the tumor. You have to have the immune cells in the right location for them to get turned on by the checkpoint inhibitors.

A lot of people, including Dmitry Gabrilovich, MD, PhD, have done a beautiful body of research showing that a protein called vascular endothelial growth factor (VEGF)—which most people think of as being responsible for forming new blood vessels to feed tumors—also has direct effects on shutting down the immune system in tumors.

The concept of the trial is basically to use a VEGF blocker to sort of prime the tumor environment and hopefully get immune cells into the tumor, and then use the checkpoint inhibitor to turn them on.
..
..
http://www.targetedonc.com/news/new-agents-targets-continue-to-emerge-in-sarcoma-cementing-role-for-immunotherapy

Phosphatidylserine inhibited the production of inflammatory mediators IL-6; IL-8; vascular endothelial growth factor; and, in particular, prostaglandin E(2) in IL-1ß-stimulated RA-FLS.

https://www.ncbi.nlm.nih.gov/pubmed/23507231